---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-310572"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T14:02:43.684729+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Kymera reports positive Phase 1b results for oral STAT6 degrader KT-621 in atopic dermatitis

## Summary
- KT-621 achieved 98% median STAT6 degradation in blood and 94% in skin lesions at Day 29 across both dose groups.
- Mean EASI reduction of 63% and mean peak pruritus NRS reduction of 40% across all patients; rapid onset by Day 8.
- Type 2 biomarker reductions: TARC down 74% in patients with baseline ≥1,600 pg/mL; Eotaxin-3 reductions numerically exceeded dupilumab at 52 weeks.
- First known demonstration of IL-31 reduction and FeNO reduction in AD patients via IL-4/13 pathway blockade.
- Well-tolerated with no SAEs, no treatment-related AEs, no conjunctivitis; Phase 2b BROADEN2 ongoing (data mid-2027) and BREADTH asthma trial starts 1Q26.

## SEC filing metadata
- accession: 0001193125-25-310572
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312525310572/0001193125-25-310572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312525310572/d69739d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-310572
- JSON: https://secwatch.observer/filing/0001193125-25-310572.json
- Plain text: https://secwatch.observer/filing/0001193125-25-310572.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.